Evidence map›Paper›PMID 42662853›Full record

ArticleJournal of bone oncology2026

Dissociated skeletal response to first-line immunotherapy in synchronous bone metastatic non-small cell lung cancer patients: Clinical profiles and survival benefit of denosumab adjunction.

E Massy, N Stacoffe, M Fauvernier, M Duruisseaux, E Grolleau, M Lamkhioued, M Pérol, C Domblides, M Roche, A Stuani and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of bone oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

E MassyDépartement de Rhumatologie Sud, Centre Expert des Métastases Osseuses (CEMOS), Hôpital Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon, Pierre-Bénite F-69495, France.
N StacoffeService de Radiologie, Hôpital Lyon Sud - Centre Expert des Métastases Osseuses (CEMOS), Hôpital Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon, Pierre-Bénite F-69495, France.
M FauvernierUMR CNRS 5558 LBBE, Université Claude Bernard Lyon 1, Université de Lyon, Lyon F-69100, France.
M DuruisseauxCentre de Recherche en Cancérologie de Lyon (CRCL) - UMR INSERM 1052 CNRS 5286, Université Claude Bernard Lyon 1, Université de Lyon, Lyon F-69100, France.
E GrolleauService de Pneumologie, Hôpital Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon, Pierre-Bénite F-69495, France.
M LamkhiouedService de pneumologie, Hôpital de la Croix rousse, Hospices Civils de Lyon, Lyon F-6004, France.
M PérolDépartement de Cancérologie Médicale, Centre Léon Bérard, Lyon F-69008, France.
C DomblidesService d'Oncologie, CHU de Bordeaux, F-33000 Bordeaux, France.
M RochePlateforme Transversale de Recherche Clinique de l'Institut de Cancérologie, HCL, Pierre-Bénite F-69495, France.
A StuaniPlateforme Transversale de Recherche Clinique de l'Institut de Cancérologie, HCL, Pierre-Bénite F-69495, France.
P ClézardinLYOS INSERM UMR1033 - Université Claude Bernard Lyon 1, Université de Lyon, Lyon F-69100, France.
E BonnelyeCanther-cancer heterogeneity, plasticity and resistance to therapies, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-UMR1277, Lille, France.
J B PialatService de Radiologie, Hôpital Lyon Sud - Centre Expert des Métastases Osseuses (CEMOS), Hôpital Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon, Pierre-Bénite F-69495, France.
N GirardInstitut Curie, Department of Medical Oncology, Paris, F-75000 France - Université Paris-Saclay, Université Versailles Saint-Quentin-en-Yvelines, Versailles, F-78000, France.
C ConfavreuxDépartement de Rhumatologie Sud, Centre Expert des Métastases Osseuses (CEMOS), Hôpital Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon, Pierre-Bénite F-69495, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Patients with bone metastases (BM) from non-small cell lung cancer (NSCLC) derive less clinical benefit from immune checkpoint inhibitors (ICIs) than those without skeletal involvement. We aimed to characterize bone-specific disease control profiles under first-line ICI therapy and explore the association of denosumab with clinical outcomes. Methods: We conducted a multicenter retrospective study in BM-NSCLC patients, naïve to systemic therapy, treated with first-line ICI monotherapy, with or without denosumab. Radiological response in soft tissue and bone compartments was assessed at 6 months using iRECIST. Disease control (DCR: iCR, iPR, or iSD) and dissociated response (discordant DCR between compartments) were predefined. Denosumab impact was evaluated using logistic regression and Cox models. Results: Sixty-one patients were included (16 women [26%]; mean age 65.8 ± 9.6 years). Soft tissue DCR was 64% and bone DCR was 62% at M6. Dissociated response occurred in 21% ( Conclusion: ICI-driven immune activation does not translate uniformly across compartments. Female sex,

Indexed as

Bone metastasesDenosumabDissociated responseImmune checkpoint inhibitorsNon-small cell lung Cancer

Identifiers

PMID42662853
PMCPMC13520977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.